Sunshine Biopharma (SBFM) 0.0129 $SBFM Sunshine

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sunshine Biopharma (SBFM) 0.0129 $SBFM

Sunshine Biopharma Acquires the US Patent for Its Anticancer Compound, Adva-27a
Marketwired - Fri Oct 09, 12:01PM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for the Company's Adva-27a anticancer compound. The Patent Purchase Agreement executed today provides Sunshine with ownership of the patent, which includes all rights to this intellectual property within the United States. Prior, Sunshine had been licensing the right to use this patent from Advanomics Corporation, a privately held Canadian company that currently owns approximately 23% of Sunshine's issued and outstanding Common Stock. The executed Patent Purchase Agreement also terminates the License Agreement between Sunshine and Advanomics and eliminates all obligations of Sunshine thereunder.

Sunshine Biopharma Announces That the Initial Manufacturing Sample of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving the Way for Clinical Trials
Marketwire Canada - Tue Aug 04, 10:15AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has completed analysis of the initial Adva-27a manufacturing sample received in June. The results show that the sample meets all of the biological specifications, clearing the way for the manufacturing of a 2-kilogram quantity for clinical trials.

Sunshine Biopharma to Receive This Week a Sample From the Adva-27a Manufacturing Currently Underway at Lonza in Switzerland
Marketwired - Tue May 26, 8:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that Lonza Ltd will ship this week a sample of the Company's Adva-27a anticancer compound for biological testing. Lonza is the Company's cGMP drug manufacturing partner in Switzerland where Adva-27a is currently being manufactured for clinical trials for Pancreatic Cancer and Multidrug Resistant Breast Cancer. Upon receipt of the sample Sunshine will perform a series of standardized cytotoxicity assays and other testing to verify the biological activity of the material and provide feedback to Lonza for the next step in the manufacturing process.

Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering Adva-27a Anticancer Compound in India
GlobeNewswire - Tue Mar 24, 9:00AM CDT
Sunshine Biopharma Inc. (OTCQB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that a "Notice of Allowance" for the patent application covering its lead antitumor compound, Adva-27a, has recently been issued in India. The allowed claims in India are nearly identical to those already issued in the United States (US Patent Number 8,236,935) where Sunshine Biopharma is the exclusive licensee. In addition to the U.S. and India, Adva-27a patents are issued in Europe and Canada. Sunshine Biopharma has previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells. Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. The GMP manufacturing of two kilograms of Adva-27a for clinical trials is currently underway at LONZA LTD in Switzerland. Sunshine Biopharma is planning to conduct the clinical trials of Adva-27a at McGill University's Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will be performed in accordance with FDA approved protocols for direct filing of the results in the U.S.

Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Marketwire Canada - Wed Nov 19, 10:00PM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a. Lonza's expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine's Adva-27a. Lonza's manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high containment cytotoxic facility in Visp, Switzerland.

Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma's Lead Anticancer Compound, Adva-27a
ACCESSWIRE - Mon Nov 03, 4:00AM CST
Montreal, Quebec / ACCESSWIRE / November 3, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has conducted a scientific review of the mechanisms by which Ebola virus penetrates human cells and takes over their machinery to multiply rapidly and go on to infecting other cells leading to massive cell destruction and ultimately death in nearly 80% of the cases. The review found that the progression of Ebola virus infection is very similar to that of Influenza A virus, the causative agent that was responsible for the death of over 90 million people in the 1918 flu pandemic. In severe Influenza A virus infections, a condition associated with high mortality rate called haemophagocytic lymphohistiocytosis (HLH) is developed by the affected patient. HLH has previously been treated successfully with Etoposide which increased survivability from 50% to 90% (LANCET, Volume 367, Pages 870-873, March 2006). Etoposide is an anticancer drug that inhibits the activity Topoisomerase II, an essential enzyme found in hyperactive, rapidly growing cells such as cancer cells and HLH cells. Like Etoposide, Sunshine Biopharma's lead anticancer compound, Adva-27a, is a Topoisomerase II inhibitor however it has been shown to be more effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The latter characteristics make Adva-27a superior to Etoposide for possible treatment of Ebola patients with already weakened state of health.

Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
Marketwired - Tue Oct 14, 7:06AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.

Sunshine Biopharma's Wholly Owned Canadian Subsidiary Completes the SOP's Required by Health Canada to Secure Drug Establishment License
Marketwire - Wed Oct 01, 7:02AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP's) required by Health Canada for the procurement of a Drug Establishment License (DEL). The completed SOP's comprise 18 binders and over 2,000 pages of documentation. It is necessary for Sunshine to have the DEL in place in order to become a fully integrated pharmaceutical company with proprietary (Adva-27a) and generic pharmaceutical products offering.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 17

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 0

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 0

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 39

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 51

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

GrandCare Health Services Enhances Revenue with Smart Solutions

Updated Category News Views 120

GrandCare Health Services Takes a New Approach to Revenue Management In a strategic move to enhance its financial efficiency, GrandCare Health Services has recently partnered with Homecare Homebase (HCHB), a leading provider of cloud-based technological solutions designed for home health agencies. This collaboration specifically focuses on optimizing revenue cycle...

Continue Reading
Westland Insurance Expands its Ontario Footprint with Acquisition

Updated Category News Views 216

Westland Insurance Expands its Ontario Presence Westland Insurance, a prominent name in Canada’s insurance market, has made strides in enhancing its reach with the acquisition of Paul Ayotte Insurance Brokers Ltd. This strategic move aims to solidify Westland’s footprint in Ontario, allowing for improved service delivery to local clients. This acquisition not only...

Continue Reading
First Industrial Realty Trust Set for Q3 Results Conference Call

Updated Category News Views 50

First Industrial Realty Trust, Inc. (NYSE: FR) faced a pivotal moment back in late 2024, gearing up to unveil its third-quarter numbers. The desks were buzzing as traders anticipated this call—a regular event but always loaded with potential surprises. Q3 Results Anticipation: Supply Chain Stakes or Investor Optimism? On that Thursday morning, scheduled for 10:00 a.m....

Continue Reading
Fannie Mae Panel Predicts Slowdown in Future Home Prices

Updated Category News Views 217

Fannie Mae's Expert Insights on Home Price Trends A recent survey conducted by Fannie Mae proves insightful for those watching the housing market, as it sheds light on anticipated changes in home prices in the coming years. The report indicates that after an increase of 5.3% in 2024, experts expect a more moderate growth of approximately 2.4% for 2025 and 2.1% for 2026....

Continue Reading
PenKid Biomarker Revolutionizes Kidney Therapy Decisions

Updated Category News Views 31

The Emergence of PenKid in Critical Care You ever get the feeling that the old ways just aren’t cutting it anymore? That’s where this penKid news rolls in like a breath of fresh air. In the world of ICU management, especially with kidney replacement therapy (KRT), this little biomarker is flipping the script on traditional biomarkers. Imagine 1,436 critically ill...

Continue Reading